De-escalation and Shortened Dual Antiplatelet Therapy in Patients at High Bleeding Risk

Definition and pathophysiological rationale

Dual antiplatelet therapy (DAPT) denotes treatment with aspirin plus a P2Y12-receptor inhibitor. In the setting of acute coronary syndrome (ACS), DAPT is used to reduce recurrent myocardial infarction, stent thrombosis and other ischemic events after coronary angiography, percutaneous coronary intervention (PCI), or medical management.

The standard post-ACS regimen is DAPT for 12 months, generally consisting of low-dose aspirin and a potent P2Y12 inhibitor, preferentially prasugrel or ticagrelor. This strategy reflects the substantial early thrombotic risk after ACS and PCI. However, antiplatelet treatment also increases bleeding risk. The optimal regimen therefore requires individualized balancing of ischemic and bleeding hazards.

High bleeding risk (HBR) should be assessed in a structured manner. Within the ARC-HBR framework, HBR is defined by the presence of at least one major criterion or two minor criteria. The source material does not provide the individual ARC-HBR criteria.

Modification of antiplatelet therapy may involve:

• reducing the duration of DAPT;

• stopping aspirin and continuing P2Y12-inhibitor monotherapy;

• switching from a potent P2Y12 inhibitor to clopidogrel;

• reducing the dose of prasugrel;

• extending DAPT beyond 12 months in carefully selected patients with high ischemic risk and low bleeding risk.

These strategies are intended primarily to reduce bleeding rather than to replace the default 12-month regimen in the general ACS population.

Clinical context and patient selection

Acute coronary syndrome

ACS includes ST-segment elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina. The initial clinical distinction depends on symptoms, serial electrocardiography, and cardiac troponin findings.

The default treatment after ACS, whether or not PCI is performed, is 12 months of DAPT unless there is a contraindication, an indication for oral anticoagulation, or an excessive risk of bleeding. The duration and intensity may be modified according to:

• bleeding risk;

• ischemic risk;

• whether revascularization was performed;

• the type of revascularization;

• stent-related risk;

• whether long-term oral anticoagulation is required;

• tolerance of treatment during the initial months.

Patients with HBR are the principal candidates for abbreviated DAPT. However, much of the evidence for shortened regimens derives from selected populations, frequently with low or intermediate ischemic risk and under-representation of patients with STEMI or other very high-risk features. Noninferiority studies designed mainly around bleeding outcomes may not reliably exclude clinically important differences in ischemic events or stent thrombosis.

Stable coronary disease and elective PCI

For chronic coronary syndromes treated with elective PCI, the standard DAPT duration is six months, usually with aspirin and clopidogrel. Shortening therapy to one to three months is an option when bleeding risk is very high. Prasugrel or ticagrelor may be considered after complex interventions.

The present chapter focuses principally on ACS, for which the evidence and recommendations differ from those applicable to elective PCI.

Clinical presentation and symptoms

The source material does not describe a distinct symptom complex caused by shortened or de-escalated DAPT. The clinical presentation prompting treatment is ACS.

Features that suggest ACS rather than chronic stable angina include:

• sudden symptoms occurring at rest or with minimal exertion;

• symptoms lasting at least 10 minutes unless treated immediately;

• severe chest pain, pressure, or discomfort;

• an accelerating pattern, with increasing frequency or severity;

• angina that awakens the patient from sleep.

Patients receiving modified antiplatelet therapy require clinical surveillance for both recurrent ischemia and bleeding. The source material does not specify a symptom-based surveillance protocol.

Evaluation and risk assessment

Initial assessment of suspected ACS

Patients with suspected ACS should undergo prompt emergency assessment, including:

• targeted history;

• physical examination;

• 12-lead ECG;

• blood sampling for high-sensitivity troponin within 10 minutes of arrival;

• continuous cardiac monitoring;

• serial high-sensitivity troponin testing;

• additional imaging or diagnostic testing when required.

Initial supportive treatment includes supplemental oxygen in patients who are hypoxemic or in heart failure, sublingual nitroglycerin for persistent angina, an aspirin loading dose, parenteral anticoagulation, a beta blocker when not contraindicated, and morphine for refractory pain.

Ischemic-risk assessment

Ischemic risk is particularly important when considering abbreviated DAPT or de-escalation. Features associated with high ischemic risk include:

• age ≥65 years;

• diabetes mellitus;

• more than one previous spontaneous myocardial infarction;

• multivessel coronary artery disease;

• chronic kidney disease;

• previous myocardial infarction;

• coronary vein graft;

• heart failure;

• complex PCI;

• other high-risk features for recurrent stent-related events.

The source material emphasizes that bleeding and ischemic risk must be considered together. A shortened regimen should not be adopted automatically in patients with a substantial risk of recurrent ischemia.

Bleeding-risk assessment

Bleeding risk should be assessed formally rather than inferred from age alone. Older age, frailty and comorbidities should be considered in addition to structured HBR criteria.

Patients with high bleeding risk who have undergone PCI may be considered for one month of DAPT followed by single-antiplatelet therapy. In other patients, particularly those who are event-free after three to six months and are not at high ischemic risk, single-antiplatelet therapy may be considered.

Diagnostics

Electrocardiography and cardiac biomarkers

The ECG and cardiac-specific troponin are central to the diagnosis of ACS and to determining the ischemic risk context in which antiplatelet therapy is prescribed.

NSTEMI is characterized by typical ischemic symptoms without persistent ST-segment elevation in at least two contiguous ECG leads, accompanied by a rise and subsequent fall in cardiac-specific troponin, with at least one value above the 99th percentile upper reference limit.

Unstable angina presents with typical ischemic symptoms without cardiac-specific troponin elevation above the 99th percentile. It generally carries a better prognosis than NSTEMI.

Persistent or nonischemic troponin elevation does not by itself establish an ACS diagnosis. Other cardiac conditions mentioned in the source material include myocarditis, takotsubo syndrome and congestive heart failure.

Coronary angiography and invasive strategy

Patients with NSTE-ACS undergo risk-based selection of an invasive strategy:

• coronary angiography within two hours for very-high-risk patients;

• angiography within 24 hours for other patients selected for an early invasive approach;

• delayed angiography more than 24 hours after presentation in appropriate cases;

• an ischemia-guided approach with initial medical management and selective angiography when there is hemodynamic instability, recurrent symptoms at rest, or ischemia on stress testing.

Routine pretreatment with a P2Y12 inhibitor is not recommended in NSTE-ACS when coronary anatomy is unknown and early invasive management within 24 hours is planned. Pretreatment may be considered when early invasive management is not expected and bleeding risk is not high.

When angiography is performed within 24 hours, P2Y12 treatment is preferentially given after angiography, provided coronary artery bypass surgery is not planned before discharge. Otherwise, it may be given on day one.

Electrophysiology

The source material does not address electrophysiological testing in relation to DAPT de-escalation or shortened therapy.

Biomarkers and laboratory findings

High-sensitivity cardiac troponin should be obtained rapidly and interpreted together with serial measurements. The magnitude of the initial concentration and the absolute change over one, two or three hours contribute quantitatively to the probability of myocardial infarction: higher initial values or larger serial changes increase the likelihood of MI.

Laboratory evaluation relevant to antiplatelet modification may include platelet function testing or CYP2C19 genotyping when a guided switch from prasugrel or ticagrelor to clopidogrel is being considered. These approaches are intended to identify an adequate response to clopidogrel.

The source material does not provide specific laboratory thresholds for bleeding risk, platelet counts, renal function, or hemoglobin.

Antiplatelet agents and practical dosing

Aspirin

The default post-ACS regimen combines aspirin with a P2Y12 inhibitor. Long-term aspirin dosing described in the source material is low-dose aspirin, 75–100 mg daily.

Aspirin is generally continued when surgery is required in a patient with an indication for DAPT. It may be stopped only as a last measure when surgical bleeding risk is very high and ischemic risk is comparably low.

Prasugrel

For escalation in a patient receiving aspirin and clopidogrel who develops ACS, prasugrel may be given as:

• loading dose: 60 mg;

• maintenance dose: 10 mg daily.

A reduction from 10 mg to 5 mg daily after one month reduced bleeding without increasing ischemic events in the cited trial population, including patients undergoing complex PCI.

Prasugrel should be withheld for seven days before surgery if discontinuation is required.

Ticagrelor

For escalation from clopidogrel after ACS, ticagrelor may be given as:

• loading dose: 180 mg;

• maintenance dose: 90 mg twice daily.

For extended treatment beyond the first year after ACS, ticagrelor 60 mg twice daily with aspirin may be preferred in selected patients with high ischemic risk who tolerated the initial 12 months without bleeding. The dose reduction from 90 mg twice daily to 60 mg twice daily after one year is described as reducing bleeding without increasing ischemic events.

Ticagrelor should be withheld for three to five days before surgery when discontinuation is necessary.

Clopidogrel

Clopidogrel is used when prasugrel or ticagrelor are unavailable, contraindicated or not tolerated. It may also be selected in older patients with ACS.

Switching from prasugrel or ticagrelor to clopidogrel is a de-escalation strategy intended to reduce bleeding. The switch may be guided by platelet function testing or CYP2C19 genotyping. Unguided switching after one month of DAPT has also reduced bleeding and net adverse events in selected populations.

Clopidogrel should be withheld for five days before surgery if discontinuation is required.

Strategies for shortening or de-escalating DAPT

Abbreviated DAPT followed by single-antiplatelet therapy

Abbreviated DAPT may consist of:

• one month of DAPT followed by aspirin or P2Y12-inhibitor monotherapy;

• three months of DAPT followed by P2Y12-inhibitor monotherapy;

• three to six months of DAPT followed by single-antiplatelet therapy, particularly in patients who are event-free and not at high ischemic risk.

In HBR patients undergoing PCI with a drug-eluting stent, one month of DAPT followed by single-antiplatelet therapy was noninferior to standard therapy for major adverse cardiac or cerebral events and reduced bleeding. Comparable findings were observed in patients undergoing complex PCI within the studied population.

For patients without HBR who remain event-free after three to six months and are not at high ischemic risk, single-antiplatelet therapy—preferably P2Y12-inhibitor monotherapy—should be considered.

In HBR patients, aspirin or P2Y12-inhibitor monotherapy after one month of DAPT may be considered.

P2Y12-inhibitor monotherapy

Stopping aspirin while continuing a P2Y12 inhibitor is a principal method of DAPT abbreviation. In the cited studies, this strategy reduced clinically relevant or major bleeding without a clear increase in ischemic events in selected populations.

Evidence is strongest for patients who:

• have completed the initial DAPT period without a major bleeding or ischemic event;

• have low to intermediate ischemic risk;

• do not have features that place them at particularly high risk of stent thrombosis or recurrent MI.

Systematic DAPT durations shorter than three months followed by clopidogrel monotherapy have not been established as useful in ACS. In one study, noninferiority for a composite of cardiovascular or bleeding events was not demonstrated.

Switching from a potent P2Y12 inhibitor to clopidogrel

De-escalation from prasugrel or ticagrelor to clopidogrel may reduce bleeding. It can be:

• guided by platelet function testing;

• guided by CYP2C19 genotyping;

• unguided after one month in selected patients.

Guided de-escalation after 48 hours or two weeks, according to the cited studies, reduced bleeding without increasing thrombotic events. A network meta-analysis found that guided selection of P2Y12 therapy provided a particularly favorable balance between bleeding and ischemic outcomes when compared with routine use of potent P2Y12 inhibitors.

De-escalation during the first 30 days after ACS is not recommended unless it is guided by testing to confirm an adequate clopidogrel response. More generally, de-escalation after the first 30 days may be considered as an alternative strategy when bleeding reduction is the objective.

Special situations requiring surgery

When time-sensitive noncardiac surgery cannot be postponed and recommended DAPT cannot be continued, possible approaches include:

• switching prasugrel or ticagrelor to clopidogrel;

• stopping aspirin and continuing prasugrel or ticagrelor alone;

• discontinuing the P2Y12 inhibitor when other measures are insufficient.

The decision should be made jointly by the surgeon and cardiologist because the risks of major surgical bleeding and premature stent thrombosis must be weighed together.

Intravenous bridging with eptifibatide, tirofiban or cangrelor is generally not recommended but may be considered rarely when DAPT interruption is unacceptable, such as in patients at very high risk of stent thrombosis, with recurrent MI, or after very recent PCI.

For excessive or life-threatening perioperative bleeding, platelet transfusion is a bailout option. However, ticagrelor and its active metabolite may inhibit transfused platelets. Albumin has been reported experimentally to bind ticagrelor and lessen its antiplatelet effect, while a neutralizing monoclonal antibody fragment remains in development and is not clinically available according to the source material.

Antithrombotic therapy when long-term oral anticoagulation is required

Patients with an indication for long-term oral anticoagulation, such as atrial fibrillation, require a different strategy because combined antithrombotic therapy substantially increases bleeding.

The general approach after ACS or PCI is:

• a short course of triple therapy with an oral anticoagulant, clopidogrel and aspirin;

• discontinuation of aspirin at discharge or within one week in most patients;

• continuation of a non-vitamin K antagonist oral anticoagulant plus clopidogrel through 12 months;

• continuation of the oral anticoagulant alone thereafter.

Shorter durations may be considered in patients at high bleeding risk:

• triple therapy for one day;

• oral anticoagulant plus clopidogrel for three to six months.

Conversely, triple therapy may be continued for up to 30 days in patients at high ischemic risk.

After 12 months, discontinuation of antiplatelet treatment in patients who remain on oral anticoagulation is recommended. Contraindications to non-vitamin K antagonist oral anticoagulants include a mechanical prosthetic heart valve, mitral stenosis, and creatinine clearance below the approved threshold for the specific drug.

Guideline recommendations

The principal recommendations for shortening and de-escalating DAPT after ACS are summarized below.

The default 12-month strategy remains preferred for most patients with ACS. Shortened or de-escalated therapy should generally be driven by a specific objective, particularly reduction of bleeding risk.

Long-term secondary prevention

After the first 12 months, single-antiplatelet therapy is generally continued in patients who do not require long-term full-dose anticoagulation. Prolonged DAPT may be considered in patients with high ischemic risk who have tolerated treatment without bleeding and do not have HBR.

Features supporting prolonged therapy include diabetes, prior MI, multivessel disease, chronic kidney disease, heart failure and coronary vein graft disease. If ticagrelor is continued beyond one year, the dose should be reduced to 60 mg twice daily.

Long-term preventive management should also address:

• smoking cessation;

• appropriate diet;

• optimal weight;

• daily exercise;

• LDL-C below 55 mg/dL;

• blood pressure control;

• glycemic control.

High-intensity statin therapy should be initiated at presentation. The stated options are atorvastatin 40–80 mg or rosuvastatin 20–40 mg, with a goal of at least a 50% LDL-C reduction and LDL-C below 55 mg/dL. Ezetimibe should be added when these goals are unlikely to be achieved with high-intensity statin therapy alone, and a PCSK9 inhibitor may be added if the target remains unmet.

Long-term treatment may also include beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and, in selected patients with type 2 diabetes, sodium-glucose cotransporter 2 or glucagon-like peptide 1 receptor agonists.

Prognosis

The principal benefit of shortened or de-escalated DAPT is a reduction in bleeding. Across the cited studies, abbreviated treatment generally reduced major or clinically relevant bleeding, while ischemic outcomes were often similar to those with longer therapy in selected populations.

Important limitations affect interpretation:

• many studies were noninferiority trials;

• most were designed primarily to assess bleeding;

• statistical power to detect ischemic differences was limited;

• stent thrombosis was not adequately assessed in some studies;

• patients with the highest ischemic risk were often excluded or under-represented;

• STEMI patients were frequently excluded or represented in small numbers;

• trial populations may not reflect the full clinical spectrum of ACS.

In patients with ACS, three months of DAPT followed by aspirin monotherapy has been associated with increased MI or stent thrombosis compared with 12 months of DAPT, although major bleeding was reduced. This finding supports caution with very early aspirin-monotherapy strategies in ACS, particularly when ischemic risk is substantial.

By contrast, shorter DAPT followed by P2Y12-inhibitor monotherapy has reduced major bleeding without a demonstrated increase in stent thrombosis, MI, stroke or death in pooled populations that included ACS, although the applicability of these findings to the highest-risk patients remains limited.

Follow-up and monitoring

Follow-up should reassess the balance between ischemic and bleeding risk, particularly at the points when treatment modification is being considered:

• at hospital discharge;

• after the first month;

• after three to six months;

• at 12 months;

• periodically during prolonged antithrombotic treatment.

The first 30 days after ACS are a particularly vulnerable period, and routine de-escalation is not recommended during this interval. In patients considered for switching to clopidogrel, platelet function testing or CYP2C19 genotyping may be used to confirm an adequate response.

At each review, treatment decisions should incorporate:

• recurrent ischemic symptoms or events;

• bleeding events;

• tolerance and adherence;

• new indications for oral anticoagulation;

• planned surgery;

• changes in renal function or comorbidity;

• whether the patient remains at high ischemic risk;

• whether HBR criteria are present.

The discharge consultation is an important opportunity to optimize antithrombotic treatment, reinforce risk-factor modification and clarify the intended duration of each antiplatelet agent.